This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
BSXPositive Net Change RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
MDTPositive Net Change MEDPPositive Net Change HIMSNegative Net Change HITIPositive Net Change
medical medical-devices
Should You Buy CareCloud, Inc. (CCLD) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CCLDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
iPower Inc. (IPW) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
IPWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exponent (EXPO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EXPOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
by Zacks Equity Research
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change VEEVNegative Net Change
medical medical-devices
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change AXGNNegative Net Change
medical medical-devices
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
ECLPositive Net Change BDXPositive Net Change DVANegative Net Change VEEVNegative Net Change
medical medical-devices
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
RMDNegative Net Change HAENegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
CPI Card Group Inc. (PMTS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PMTSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
CAHPositive Net Change TNDMNegative Net Change MEDPPositive Net Change HITIPositive Net Change
medical medical-devices
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DVANegative Net Change ALGNPositive Net Change ALCPositive Net Change DXCMPositive Net Change
medical medical-devices
Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner
by Zacks Equity Research
Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.
DVANegative Net Change ALGNPositive Net Change MEDPPositive Net Change BFLYNegative Net Change
medical medical-devices
Three Reasons to Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
ECLPositive Net Change DVANegative Net Change AMNPositive Net Change VEEVNegative Net Change
medical medical-devices
HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition
by Zacks Equity Research
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change HQYPositive Net Change
medical medical-devices
Great Southern Bancorp (GSBC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GSBCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
LHPositive Net Change RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
DVANegative Net Change ALGNPositive Net Change MEDPPositive Net Change PROFNegative Net Change
medical medical-devices
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
by Zacks Equity Research
Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.
TMOPositive Net Change MEDPPositive Net Change HIMSNegative Net Change HITIPositive Net Change
medical medical-devices
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QGENPositive Net Change MEDPPositive Net Change HIMSNegative Net Change HITIPositive Net Change
medical medical-devices
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.
RMDNegative Net Change HSICPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Merit Medical (MMSI) to Expand Product Suite Via New Launch
by Zacks Equity Research
Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.
ECLPositive Net Change DVANegative Net Change MMSIPositive Net Change VEEVNegative Net Change
medical medical-devices
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change VEEVNegative Net Change
medical medical-devices
GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy
by Zacks Equity Research
GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change GEHCNegative Net Change
medical medical-devices
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.
ALGNPositive Net Change RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices